[go: up one dir, main page]

AR042199A1 - Composicion farmaceutica liquida que comprende una cantidad terapeuticamente eficaz de al menos un compuesto de 3,7 diazabiciclo (3,3,1) nonano, metodo de tratamiento y/o profilaxis de eventos anti-arritmicos en seres humanos y producto y/o forma de presentacion farmaceutica - Google Patents

Composicion farmaceutica liquida que comprende una cantidad terapeuticamente eficaz de al menos un compuesto de 3,7 diazabiciclo (3,3,1) nonano, metodo de tratamiento y/o profilaxis de eventos anti-arritmicos en seres humanos y producto y/o forma de presentacion farmaceutica

Info

Publication number
AR042199A1
AR042199A1 ARP030104235A ARP030104235A AR042199A1 AR 042199 A1 AR042199 A1 AR 042199A1 AR P030104235 A ARP030104235 A AR P030104235A AR P030104235 A ARP030104235 A AR P030104235A AR 042199 A1 AR042199 A1 AR 042199A1
Authority
AR
Argentina
Prior art keywords
products
treatment
pharmaceutical composition
events
arritmic
Prior art date
Application number
ARP030104235A
Other languages
English (en)
Inventor
Matthias Straub
Claus Rudolf Steimborn
Werner Cautreels
Johannes Wihelmus Catharine Maria Jansen
Vries Michiel De
Original Assignee
Solvay Pharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Gmbh filed Critical Solvay Pharm Gmbh
Publication of AR042199A1 publication Critical patent/AR042199A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

Uso de 3,7-diazabiciclo[3,3,1]nonano, preferiblemente compuestos de 9,9-alquileno-3,7-diazabiciclo[3,3,1]nonano, y con mayor preferencia al uso de tedisamil, bertosamil y sus sales de adición de ácido y/o solvatos fisiológicamente aceptables, en la forma de una composición farmacéutica líquida para el tratamiento y/o profilaxis de eventos anti-arrítmicos en pacientes humanos, preferiblemente en la conversión de reciente proceso de fibrilación auricular o flúter auricular a ritmo sinusal normal en pacientes humanos. Métodos de tratamiento preferiblemente por administración en dos etapas y productos farmacéuticos.
ARP030104235A 2002-11-18 2003-11-17 Composicion farmaceutica liquida que comprende una cantidad terapeuticamente eficaz de al menos un compuesto de 3,7 diazabiciclo (3,3,1) nonano, metodo de tratamiento y/o profilaxis de eventos anti-arritmicos en seres humanos y producto y/o forma de presentacion farmaceutica AR042199A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42679502P 2002-11-18 2002-11-18

Publications (1)

Publication Number Publication Date
AR042199A1 true AR042199A1 (es) 2005-06-15

Family

ID=32326429

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030104235A AR042199A1 (es) 2002-11-18 2003-11-17 Composicion farmaceutica liquida que comprende una cantidad terapeuticamente eficaz de al menos un compuesto de 3,7 diazabiciclo (3,3,1) nonano, metodo de tratamiento y/o profilaxis de eventos anti-arritmicos en seres humanos y producto y/o forma de presentacion farmaceutica

Country Status (20)

Country Link
US (2) US7087620B2 (es)
EP (1) EP1565239B8 (es)
JP (1) JP2006510613A (es)
KR (1) KR101059330B1 (es)
CN (1) CN1726062A (es)
AR (1) AR042199A1 (es)
AT (1) ATE501758T1 (es)
AU (1) AU2003296580B8 (es)
BR (1) BR0316383A (es)
CA (1) CA2506083A1 (es)
DE (1) DE60336417D1 (es)
IL (1) IL168630A (es)
MX (1) MXPA05005344A (es)
NO (1) NO20053010L (es)
RU (1) RU2358732C2 (es)
SA (1) SA04250023B1 (es)
TW (1) TW200418468A (es)
UA (1) UA85546C2 (es)
WO (1) WO2004045591A2 (es)
ZA (1) ZA200504049B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200418468A (en) * 2002-11-18 2004-10-01 Solvay Pharm Gmbh Liquid pharmaceutical formulations containing 3,7-diazabicyclo[3,3,1]nonane compounds and method of treatments relating to anti-arrhytmic events
CA2533492A1 (en) * 2003-07-21 2005-02-10 Solvay Pharmaceuticals Gmbh Use of 3,7-diazabicyclo[3,3,1]nonane compounds for the treatment and/or prophylaxis of anti-arrhythmic events in male human patients
US20050054667A1 (en) * 2003-07-21 2005-03-10 Solvay Pharmaceuticals Gmbh Method of treating or inhibiting anti-arrhythmic events in male human patients
CA2617519A1 (en) * 2005-08-23 2007-03-01 Astellas Pharma Inc. Agent for treating atrial fibrillation
EP2149370A1 (en) * 2008-07-31 2010-02-03 Neuroscienze Pharmaness S.C. A R.L. Diazabicyclic compounds and microemulsions thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4550111A (en) * 1982-01-29 1985-10-29 Imperial Chemical Industries Plc Alkanolamine derivatives
DE3234697A1 (de) * 1982-09-18 1984-03-22 Kali-Chemie Pharma Gmbh, 3000 Hannover Neue diazabicyclo-(3,3,1)-nonane
PT88381B (pt) * 1987-09-09 1995-07-06 Kali Chemie Pharma Gmbh Processo para a preparacao de novos compostos 3,7-diazabiciclo{3,3,1} nonano, e de composicoes farmaceuticas que contem estes compostos
DE4019080A1 (de) * 1990-06-15 1991-12-19 Kali Chemie Pharma Gmbh Neue 3,7-diazabicycolo (3,3,1)nonan-verbindungen enthaltende arzneimittel
DE4139763A1 (de) * 1991-12-03 1993-06-09 Kali-Chemie Pharma Gmbh, 3000 Hannover, De Kristalline fumarsaure salze von 9,9-alkylen-3,7-diazabicyclononan-verbindungen und diese verbindungen enthaltende arzneimittel
DE4402933A1 (de) * 1994-02-01 1995-08-03 Kali Chemie Pharma Gmbh Neue 3-Benzoyl-3,7-diazabicyclo[3,3,1] nonan-Verbindungen enthaltende Arzneimittel
DE4402931A1 (de) * 1994-02-01 1995-08-03 Kali Chemie Pharma Gmbh Neue 3-Phenylsulfonyl-3,7-diazabicyclo[3,3,1] nonan-Verbindungen enthaltende Arzneimittel
US5576349A (en) * 1995-11-30 1996-11-19 The General Hospital Corporation Retionoic acid treatment of cardiac arrhythmia
US6026817A (en) * 1996-11-14 2000-02-22 Clemens; Anton H. Method of treating the syndrome of coronary heart disease risk factors in humans
SE9704709D0 (sv) * 1997-12-17 1997-12-17 Astra Ab Pharmaceutically active compounds
US6790463B2 (en) * 2001-03-30 2004-09-14 Robert F. Hofmann Uses of targeted oxidative therapeutic formulation in arteriosclerosis
DE10131217A1 (de) * 2001-06-28 2003-01-09 Solvay Pharm Gmbh 3-Phenyl-3,7-diazabicyclo 3,3,1 nonan-Verbindungen sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
TW200418468A (en) * 2002-11-18 2004-10-01 Solvay Pharm Gmbh Liquid pharmaceutical formulations containing 3,7-diazabicyclo[3,3,1]nonane compounds and method of treatments relating to anti-arrhytmic events

Also Published As

Publication number Publication date
ZA200504049B (en) 2006-07-26
DE60336417D1 (de) 2011-04-28
AU2003296580B2 (en) 2010-02-18
KR20050116125A (ko) 2005-12-09
US20050261300A1 (en) 2005-11-24
WO2004045591A2 (en) 2004-06-03
BR0316383A (pt) 2005-10-04
KR101059330B1 (ko) 2011-08-24
CA2506083A1 (en) 2004-06-03
SA04250023B1 (ar) 2008-12-23
RU2005119280A (ru) 2006-03-20
WO2004045591A3 (en) 2004-07-22
US7087620B2 (en) 2006-08-08
IL168630A (en) 2013-08-29
EP1565239B1 (en) 2011-03-16
CN1726062A (zh) 2006-01-25
JP2006510613A (ja) 2006-03-30
UA85546C2 (en) 2009-02-10
ATE501758T1 (de) 2011-04-15
AU2003296580A1 (en) 2004-06-15
US20040152716A1 (en) 2004-08-05
MXPA05005344A (es) 2005-08-03
RU2358732C2 (ru) 2009-06-20
EP1565239B8 (en) 2011-06-22
AU2003296580B8 (en) 2010-03-18
TW200418468A (en) 2004-10-01
NO20053010L (no) 2005-06-20
EP1565239A2 (en) 2005-08-24

Similar Documents

Publication Publication Date Title
CA2389167A1 (en) Pharmaceutical formulations of resveratrol and methods of use thereof
UY26372A1 (es) "imidazo-3-il-aminas bicíclicas procedimiento para su preparación y medicamentos que las contienen "
CO5170471A1 (es) Tabletas de liberacion modificada que incluyen amoxilina y clavulanato de potasio
ES2109899T1 (es) Metodo, composiciones y kits para aumentar la biodisponibilidad oral de agentes farmaceuticos.
NO20080827L (no) Faste doseringsformuleringer av narkotiske legemidler som har forbedret bukal adsorpsjon
CY1115484T1 (el) Ενωσεις, συνθεσεις και μεθοδοι για την θεραπεια αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων, οπως νοσος alzheimer, διαβητης τυπου 2 και νοσος parkinson
ATE297723T1 (de) Pharmazeutische zusammensetzung enthaltend ein 5- aminolaevulinsäure-ester als photochemotherapeutikum und ein mucoadhäsivum
ES2233931T3 (es) Fenilacetato y derivados, solos o en combinacion con otros compuestos, contra estados neoplasicos y otros trastornos.
UY30537A1 (es) Formulaciones de flibanserina y metodo para fabricarlas
WO2001087284A3 (en) Aldosterone antagonist composition for release during aldosterone acrophase
WO2008142572A3 (en) Controlled release tablet formulation containing magnesium aluminometasilicate
AR039164A1 (es) Sales de venlafaxina de baja solubilidad en agua
ES2045182T3 (es) Substancias fisiologicamente activas, un proceso para la preparacion de las mismas y composiciones farmaceuticas que las contienen.
NO341573B1 (no) Faste formuleringer av ospemifen og fremgangsmåte for fremstilling av ospemifen
ES2193233T3 (es) Uso de amiodipina, una sal de la misma o felodipina en combinacion con un inhibidor ace en la fabricacion de un medicamento para el tratamiento de insuficiencia cardiaca conjuntiva no isquemica.
AR001765A1 (es) Una formulación de liberación prolongada un procedimiento para su preparación una forma cristalina de cisaprida-(l)-tartrato y un medicamento util para el tratamiento de trastornos gastrointestinales
WO2003092655A3 (de) Verwendung von wirkstoffmischungen mit azelainsaure und glycyrrhetinsaure als anti-aknemittel
AR042199A1 (es) Composicion farmaceutica liquida que comprende una cantidad terapeuticamente eficaz de al menos un compuesto de 3,7 diazabiciclo (3,3,1) nonano, metodo de tratamiento y/o profilaxis de eventos anti-arritmicos en seres humanos y producto y/o forma de presentacion farmaceutica
WO2020170035A3 (en) Method for treatment of rosacea including patient reported outcomes thereof
AR006281A1 (es) Utilizacion de (+)-alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4- piperidinometanol o sus sales de adicion de acidos farmaceuticamenteaceptables en el tratamineto de trastornos depresivos y trastornos bipolares
WO2006115770A3 (en) Orally disintegrating pharmaceutical tablet formulations of olanzapine
MY130445A (en) Novel formulations of alpha-2, 4-disulfophenyl-n-tert-butylnitrone
AR039162A1 (es) Formulaciones de venlafaxina de liberacion extendida
AR030551A1 (es) Uso de nefiracetam para la fabricacion de un medicamento para eltratamiento de la neurodegeneracion y composicion farmaceutica resultante
AR023452A1 (es) Utilizacion del osanetant para preparacion de medicamentos utiles en el tratamiento de los trastornos del humor

Legal Events

Date Code Title Description
FA Abandonment or withdrawal